Strategic shift to fully focus on ReNeuron’s Proprietary Exosomes Platform
Strategic shift to fully focus on ReNeuron’s Proprietary Exosomes Platform
ReNeuron has negotiated a Supplemental Terms Agreement with potential to generate revenue of up to £6m
11 February 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Olav Hellebø is standing down as CEO and executive director of the Company and will leave the Company on 28 February 2022.
11 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3 March 2022, heading up the Research team as Vice President of Research and will report directly into the CEO.
30 November 2021: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell and Exosome Technologies, announces its interim results for the six months ended 30 September 2021.
18 November 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2021 and business update on Tuesday 30 November 2021.
18 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on changes to the Company’s Board of Directors.
6 January 2021: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, will host a conference call for analysts at 10.00am GMT today to discuss the Company’s recent half year results, fundraising and outlook for the year ahead.
10 September 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting (“AGM”).
31 July 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that the US Patent and Trademark office (USPTO) has completed its examination of the Company’s patent application (14/379,239), entitled: “Phenotype profile of human retinal progenitor cells” and has issued a notification of allowance for the issuance of a patent.